OBJECTIVE: To review the epidemiology of Haemophilus influenzae type b (Hib) disease,
the first Hib vaccine and its limitations, the characteristics and clinical efficacy of the newer …

Background The bacterium, Haemophilus influenzaetype B (Hib), is an important cause of
infections in infants and young children; severe disease in adults due to Hib is uncommon …

These recommendations include information on use of two vaccines recently licensed for
use with infants: Haemophilus b Conjugate Vaccine (Diphtheria CRM 197 Protein …

Background. The development of a vaccine against Haemophilus influenzae type b (Hib)
was stimulated by its recognition as a major pathogen of early childhood. The first vaccine to …

Abstract Purpose On 13 December 2007, Merck & Co., Inc. voluntarily recalled 1.2 million
doses of Haemophilus influenzae type b (Hib) vaccines that had been distributed since April …

Prior to the introduction of vaccines, Haemophilus influenzae type b (Hib) was the most
common cause of bacterial meningitis and an important cause of severe pneumonia in …

Haemophilus influenzae type b (Hib) conjugate vaccines prevent Hib disease in individuals
and reduce the carriage and transmission of the organism in the community. The incidence …

This Policy Statement was retired May 1997. This updated statement on Haemophilus
influenzae type b conjugate vaccines includes recommendations for use of a newly licensed …

On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix
(GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) …